Laboratory studies suggest that mechanisms of resistance to tyrosine kinase inhibitor therapy differ between the specific subtypes of HER2-positive breast cancer.
Original Article: HER2+ Breast Cancer Subtypes Resistant to TKIs Through Differing Mechanisms